Log in

2595 Genfleet Therapeutics (Shanghai), Inc. HKEX · China

Genfleet Therapeutics (Shanghai) (2595) news

Genfleet Therapeutics (Shanghai), Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2595, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Genfleet Therapeutics (Shanghai) news

We have not published a story on Genfleet Therapeutics (Shanghai) yet. When there is news, it will appear here.

Questions about Genfleet Therapeutics (Shanghai)

What is the ticker symbol of Genfleet Therapeutics (Shanghai)?

Genfleet Therapeutics (Shanghai), Inc. trades under the ticker 2595 on HKEX.

Where is Genfleet Therapeutics (Shanghai) listed?

Genfleet Therapeutics (Shanghai), Inc. is listed on HKEX. Our directory also records these other listings: GETTEX:Y3L.

Which country or territory is Genfleet Therapeutics (Shanghai) listed under?

Our directory records Genfleet Therapeutics (Shanghai), Inc. under China.

What does Genfleet Therapeutics (Shanghai) do?

Our directory classifies Genfleet Therapeutics (Shanghai), Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Genfleet Therapeutics (Shanghai)?

The ISIN recorded for Genfleet Therapeutics (Shanghai), Inc. is CNE1000074L2.

Does aibio.space cover Genfleet Therapeutics (Shanghai)?

aibio.space lists Genfleet Therapeutics (Shanghai), Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Genfleet Therapeutics (Shanghai)?

Companies in our directory listed in the same country and business area as Genfleet Therapeutics (Shanghai): Zhong Zhu Healthcare Holding Co., Acrobiosystems Co., BIOSTAR PHARMACEUTICALS INC, China Resources Boya Bio-pharmaceutical Group Co., Chengdu Easton Biopharmaceuticals Co., Hainan Haiyao Co..

Investor discussion: Genfleet Therapeutics (Shanghai)

Members talk about Genfleet Therapeutics (Shanghai) (2595). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Genfleet Therapeutics (Shanghai), newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source

  2. Financings

    Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source

  3. Financings

    Share or debt issue: CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING. Source

  4. Financings

    Share or debt issue: (1) PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME (2) PROPOSED ADOPTION OF THE H SHARE INCENTIVE SCHEME (3) PROPOSED AUTHORISATION TO THE BOARD OF DIRECTORS AND/OR AUTHORIZED PERSON(S) TO HANDLE MATTERS RELATED TO THE SHARE SCHEMES (4) PROPOSED GRANT OF GENERAL MANDATE TO REPURCHASE H SHARES (5) PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND (6) NOTICE OF THE EXTRAORDINARY GENERAL MEETING. Source

  5. Financings

    Share or debt issue: GLOBAL OFFERING. Source

Press releases

Headlines of Genfleet Therapeutics (Shanghai)'s own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT Initial Clinical Readout of GFH276 (an Oral Molecular-glue Pan RAS Inhibitor) Presented as Late-breaking Abstract (LBA) at 2026 ESMO Annual Meeting, Demonstrating Promising Clinical Potential and Favorable Safety in Pretreated RAS-mutant Solid Tumors

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT GFH375/VS-7375 (Oral KRAS G12D Inhibitor) Achieves Positive Progress across Multiple Clinical Studies in China and Abroad, with Promising Efficacy in Various RAS-mutant Solid Tumors

  3. HKEXnews

    RESIGNATION OF NON-EXECUTIVE DIRECTOR

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276

  5. HKEXnews

    ANNOUNCEMENT PURSUANT TO RULE 13.10 OF THE LISTING RULES

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT GFH375, Oral KRAS G12D Inhibitor, Advances into a Phase II Study Evaluating Monotherapy and Combination Regimens with EGFR Antibody or Chemotherapy in First-line Treatment of Non-small Cell Lung Cancer

  9. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT GFH375 Advances into A Novel Phase II Study Featuring Two First-in-world Combination Therapies for Pancreatic Cancer, including the Regimens of RAS-Targeted Inhibitor Plus Cachexia Bispecific Antibody and a Combination of Dual RAS Inhibitors Built on Distinct Mechanisms of Action

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT World's First Registrational Phase III Study for Oral KRAS G12D Inhibitor in NSCLC Advances, as First Patient Dosed in GFH375's Second Registrational Study

  12. HKEXnews

    ARTICLES OF ASSOCIATION

  13. HKEXnews

    COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  14. HKEXnews

    PLACING OF NEW H SHARES UNDER GENERAL MANDATE

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE ON THE MARKET

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT GFH375 Monotherapy Data Presented at 2026 ASCO Oral Session: World's First Dedicated Data of a RAS Inhibitor for Cholangiocarcinoma Show Preliminary Efficacy; Monotherapy Activity Observed together with Prospects for Combinational Regimens in Colorectal Cancer Treatment

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT Preliminary Phase I Data of GFS202A for Cachexia Presented in Poster Session of 2026 ASCO Annual Meeting, Featuring Favorable Safety Profile and Robust Clinical Potential with Body Weight, Skeletal Muscle and Appetite Improvements

  18. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 11, 2026

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT Statement on the Proprietary Intellectual Property Status of GFH276, a Pan RAS (ON) Inhibitor

  20. HKEXnews

    NOTICE OF THE 2025 ANNUAL GENERAL MEETING

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2595 on TradingView.

Listing details

Genfleet Therapeutics (Shanghai), Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2595, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Genfleet Therapeutics (Shanghai), Inc.
Ticker
2595
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE1000074L2
Other listed symbols
GETTEX:Y3L
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.